Compugen Ltd. CGEN
announced today that pre-clinical findings presented at the 3rd
European Congress of Immunology provide additional support for the
potential of CGEN-15001 to effectively treat autoimmune disease. Mode of
action studies for CGEN-15001 demonstrated both the active suppression
of pathogenic immune responses and the reestablishment of immune balance
by increasing anti-inflammatory mediators and promoting inducible
regulatory T cells (iTregs). Modulation of iTregs is considered an
extremely promising approach for treatment of autoimmunity and cancer,
and therefore has been the focus of intense industry and academic
research in recent years.
These results were included in a presentation focused on CGEN-15001 by
Dr. Joseph R. Podojil, a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in